ERBB2 and breast carcinoma: Through these significant observations, our study uncovers TrkA-mediated STAT3 phosphorylation as a novel mechanism underlying the crosstalk between the JAK2–STAT3 and TrkA pathways in triple-negative and HER2-enriched breast cancers, and it identifies the novel prognostic value for the pathway co-activation.